What Is Ozempic?

1. Three Indications

The injection label lists three uses, and each came from its own trial.

Glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. This is the original 2017 indication and the SUSTAIN program behind it. Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, from SUSTAIN-6. Kidney protection: reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, from FLOW.

The tablets carry the first two. Their cardiovascular indication comes from SOUL, a trial of oral semaglutide in 9,650 adults with type 2 diabetes and cardiovascular or kidney disease, where major events occurred in 12.0% against 13.8% on placebo, hazard ratio 0.86.

What is not on any Ozempic label is weight reduction. Semaglutide is approved for that as Wegovy, whose injection goes to 2.4 mg and 7.2 mg where Ozempic stops at 2 mg. The Ozempic vs Wegovy page covers that split.

2. What the Trials Showed

On weight, which is not an indication but is what many people ask about: the one trial of an Ozempic dose in people with obesity is STEP 2, in type 2 diabetes, where semaglutide 1 mg produced 7.0% mean weight loss over 68 weeks against 9.6% for the 2.4 mg Wegovy dose and 3.4% for placebo. Head-to-head against tirzepatide, semaglutide 1 mg lost 5.7 kg to tirzepatide’s 7.6 to 11.2 kg in SURPASS-2; the Ozempic vs Mounjaro page has that trial in full.

3. The Dose Ladders

Both forms start at a dose the label describes as not effective for glycemic control. Its purpose is tolerability.

The injection escalates only when glucose control calls for it, and 0.5 mg is a maintenance dose in its own right. The tablets are taken on waking, on an empty stomach, with up to 4 ounces of water, followed by a 30-minute wait before food, drink, or other pills. The label states that Ozempic tablets and Rybelsus are not substitutable milligram for milligram, though their steady-state exposures match step for step: 1.5, 4, and 9 mg of Ozempic tablets correspond to 3, 7, and 14 mg of Rybelsus. The titration schedule tool builds a dated calendar for the injection ladder.

4. Missed Doses and Timing

The injection can be taken on any day at any time, with or without meals. The day can be changed as long as two doses are at least 48 hours apart. A missed injection can be taken within 5 days; after that, skip it and take the next one on the regular day. A missed tablet is skipped, with the next taken the following day. The missed-dose tool applies each rule to a date.

The reason for the 5-day window is the half-life. Semaglutide’s is about one week, it reaches steady state after four to five weeks of dosing, and the label says it is present in circulation for about five weeks after the last dose.

5. Safety

The label opens with a boxed warning on thyroid C-cell tumors seen in rodents, with a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Warnings cover acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or a sulfonylurea, acute kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, acute gallbladder disease, and pulmonary aspiration under anesthesia.

In the label’s pooled placebo-controlled trials, the common side effects were nausea (15.8% on 0.5 mg, 20.3% on 1 mg, 6.1% on placebo), vomiting (5%, 9.2%, 2.3%), diarrhea (8.5%, 8.8%, 1.9%), abdominal pain, and constipation. They cluster during escalation. The drug is not for use in pregnancy and should be stopped at least two months before a planned pregnancy.

6. Ozempic, Wegovy, and Rybelsus

Same molecule, three labels, so that each carries only the indications its own trials support. Ozempic vs Rybelsus covers the injection-versus-tablet question in depth.

7. Tracking Ozempic

A week-long half-life means each dose overlaps the last several, so the useful record is product, form, date, milligrams, and injection site. How GLP-1 tracking works covers what to log.

8. What Is Ozempic FAQ

• What is Ozempic in simple terms?

  A prescription GLP-1 receptor agonist, semaglutide, made by Novo Nordisk for adults with type 2 diabetes. It comes as a once-weekly injection pen and, more recently, as a once-daily tablet. It lowers blood sugar, causes weight loss as a side effect, and reduces heart and kidney complications of diabetes in trials.

• Is there an Ozempic pill?

  Yes. Ozempic tablets in 1.5, 4, and 9 mg are approved for type 2 diabetes and cardiovascular risk reduction. They share a prescribing label with Rybelsus, are taken on an empty stomach with up to 4 ounces of water followed by a 30-minute wait, and are not interchangeable with Rybelsus milligram for milligram.

• Is Ozempic approved for weight loss?

  No. Ozempic's label covers type 2 diabetes and its heart and kidney complications. Semaglutide for weight reduction is Wegovy, which goes to 2.4 mg and 7.2 mg where Ozempic stops at 2 mg. Whether either is prescribed is a prescriber's decision and often a coverage question.

• What if I miss an Ozempic dose?

  For the injection, the label says take it as soon as possible within 5 days of the missed dose; if more than 5 days have passed, skip it and take the next dose on the usual day. For the tablets, skip the missed dose and take the next one the following day. Never double up.

• What are the main side effects?

  Gastrointestinal, mostly during dose escalation. In the label's placebo-controlled trials, nausea occurred in 20.3% on 1 mg against 6.1% on placebo, vomiting in 9.2% against 2.3%, diarrhea in 8.8% against 1.9%. The serious warnings cover pancreatitis, gallbladder disease, kidney injury from dehydration, retinopathy complications, and hypoglycemia with insulin or sulfonylureas.

9. Sources